The glucagon-like-peptide-1 (GLP-1) analogue dulaglutide (Trulicity®) has been studied in other disease areas as a therapeutic option to reduce appetite and weight, and is hence a promising preventive option. No standard prevention of weight gain for patients receiving these medications has yet been established. Weight gain is the most common side effect in patients treated with second generation antipsychotics (SGAs), especially in those receiving olanzapine and clozapine. Besides psychotherapy, antipsychotic medications are the main treatment option, although inducing major side effects. Introduction: Schizophrenia spectrum disorders are characterized by delusions, hallucinations and perceptual disturbances and lead to increased personal and economic burden.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |